Amgen Gets Panitumumab Priority Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen's panitumumab has an estimated mid-September user fee date under FDA priority review for metastatic colorectal cancer patients failing prior chemotherapy, the company announced June 12